3.
多靶点药物vs单靶点药物单药治疗NSCLC疗效对比
Outcome of multi-targeted vs mono-targeted TKIs in NSCLC
| Study | Drug | n | Median PFS (week) | Median OS (week) | ORR (%) | DCR (%) |
| DCR: disease control rate. | ||||||
| Socinski | Sunitinib | 63 | 11.3 | 24 | 9.5% | 52% |
| Blumenschein | Sorafenib | 52 | 11.9 | 29 | 0% | 59% |
| Ronald B | Vandetanib | 83 | 11 | 24 | 8% | 45% |
| BR21 | Erlotinib | 488 | 9.4 | 28.7 | 6.9% | 43.0% |
| Interest | Gefitinib | 659 | 9.4 | 32.6 | 9.7% | 45.8% |